The Viral/Molecular Core (Core D) provides reagents, facilities, lab services, consultation &training in support of innovative, multidisciplinary and translational HIV/AIDS research on the Penn/CHOP/Wistar campus with the broad goal of advancing collaborative research in the pathogenesis, treatment, and prevention of HIV/AIDS, serving CFAR investigators from multiple programs. The specific Core activities supporting this goal are to provide: ? Virology services including a repository of HIV-1 prototype, primary and mutant strains;virus isolation from patient samples;amplification of virus working stocks;structurally intact inactivated virions;HIV p24 and SIV p27 ELISA assay;and other viral services. ? Molecular services including support for realtime qPCR along with reagents, optimized primer-probe sets and custom primer/probe development;viral genotyping or cloning from clinical specimens;molecular virology support for translational research programs;and in the next cycle a new high density pyrosequencing service. ? Education, training, consultation and leadership in molecular virology activities including training in BSL3 practices for CFAR members lab personnel;training and consultation in virological and molecular techniques for CFAR investigator personnel;facilitating the dissemination and adoption of new technologies; and collaboration with and support of other Cores and campus programs in their HIV/AIDS research-related educational efforts. During the current funding cycle the Core provided support to 46 CFAR investigators, contributing to novel gene therapy approaches to HIV infection;better understanding of integration and establishment of latency;new approaches to vaccine design;advances in viral entry and resistance to entry inhibitors;effects of neuroimmune mediators &drugs of abuse;HIV neuropathogenesis;and other areas. The V/M Core has evolved significantly over the past 9 years in response to CFAR member needs and user feedback, levels of utilization, and internal &external advisory input, and collaborates closely with other CFAR Cores in support of these goals. The Core has been directed since its inception by Drs. Ronald Collman (director) and Luis Montaner (co-director) and, going forward, will be joined by Dr. F. (Rick) Bushman (co-director) to supervise the introduction and dissemination of new molecular sequencing technologies to CFAR investigators.

Public Health Relevance

The Viral/Molecular Core provides laboratory services, reagents, facilities, training and support in the area of fundamental virology and molecular biology in order to enhance the ability of investigators on campus to carry out innovative research on the pathogenesis, treatment and prevention of HIV/AIDS utilizing state-ofthe art technology, optimal virus strains, maximal efficiency and the highest level of biosafety.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI045008-15
Application #
8505349
Study Section
Special Emphasis Panel (ZAI1-SV-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
15
Fiscal Year
2013
Total Cost
$257,952
Indirect Cost
$84,795
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Gross, Robert; Bandason, Tsitsi; Langhaug, Lisa et al. (2015) Factors associated with self-reported adherence among adolescents on antiretroviral therapy in Zimbabwe. AIDS Care 27:322-6
Muluneh, Melaku; Shang, Wu; Issadore, David (2014) Track-etched magnetic micropores for immunomagnetic isolation of pathogens. Adv Healthc Mater 3:1078-85
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
Nachega, Jean B; Parienti, Jean-Jacques; Uthman, Olalekan A et al. (2014) Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. Clin Infect Dis 58:1297-307
Wohl, David A; Arnoczy, Gretchen; Fichtenbaum, Carl J et al. (2014) Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther 19:141-7
Zetola, Nicola M; Modongo, Chawangwa; Olabiyi, Bisayo et al. (2014) Examining the relationship between alcohol use and high-risk sex practices in a population of women with high HIV incidence despite high levels of HIV-related knowledge. Sex Transm Infect 90:216-22
Haas, David W; Kwara, Awewura; Richardson, Danielle M et al. (2014) Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. J Antimicrob Chemother 69:2175-82
Ramirez, Lorenzo A; Daniel, Alexander; Frank, Ian et al. (2014) Seroprotection of HIV-infected subjects after influenza A(H1N1) vaccination is directly associated with baseline frequency of naive T cells. J Infect Dis 210:646-50
Liu, Weimin; Li, Yingying; Shaw, Katharina S et al. (2014) African origin of the malaria parasite Plasmodium vivax. Nat Commun 5:3346
Blank, Michael B; Hennessy, Michael; Eisenberg, Marlene M (2014) Increasing quality of life and reducing HIV burden: the PATH+ intervention. AIDS Behav 18:716-25

Showing the most recent 10 out of 235 publications